research reports and media, page-1519

hardly PAR's job to list competitor's...

WOMAC pain function not statistically meaningful on general group, showed hope on a specific subgroup

https://www.medpagetoday.com/rheumatology/arthritis/86677


The Wnt pathway modulator lorecivivint failed to meet the primary endpoint in a phase IIa study for knee osteoarthritis (OA), but showed promise in certain patient subgroups, researchers reported.
On the primary endpoint, which was improvement in pain on the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index, no dose of intra-articular lorecivivint (0.03 mg, 0.07 mg, or 0.23 mg) showed statistically significant differences from placebo at week 13, according to Yusuf Yazici, MD, of NYU Langone Medical Center in New York City, and colleagues. Yazici is also chief medical officer of Samumed, the study sponsor.

However, in a post-hoc exploratory analysis of a subgroup of patients who had unilateral knee pain, patients receiving the 0.07-mg dose had significant improvements at week 52 on WOMAC pain scores, with a between-group difference of -8.73 (95% CI -17.44 to -0.03, P=0.049), and also on function scores, with a between-group difference of -10.26 (95% CI -19.82 to -0.69, P=0.036), they reported online in Arthritis & Rheumatology.